Selective Androgen Modulator for Autoimmune Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic autoimmune and inflammatory disorders, such as multiple sclerosis and diabetes, often have limited effectiveness and are associated with significant side effects, necessitating the development of novel compounds that can modulate immune responses and metabolic pathways without causing toxicities.
Innovation Solution
The development of compounds like 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, which selectively modulate CD4+CD25+ regulatory T cells and inhibit NF-κB activity, while minimizing activation of glucocorticoid and androgen receptors, to treat autoimmune and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoid receptor agonists are used to treat inflammation, then NF-κB activity is inhibited, but unwanted toxicities including immune suppression and loss of bone mass occur
Solution Approach 1:
The patent changes the molecular parameters of the compound to achieve selective NF-κB inhibition without GR activation. The compound 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol has specific structural modifications (4α-fluoro substitution, 17α-ethynyl group) that alter its binding affinity and selectivity, allowing it to inhibit NF-κB while avoiding the toxic effects of non-selective GR agonists
Solution Approach 2:
The compound acts as an intermediary agent that selectively modulates NF-κB activity without directly activating GR. It serves as a selective modulator that achieves the desired anti-inflammatory effect through NF-κB inhibition while avoiding the harmful downstream effects of GR activation, thus mediating the therapeutic effect with minimal toxicity
2Reliability
If existing treatments for autoimmune disorders are used, then disease progression is addressed, but significant side effects are associated with the treatments
Solution Approach 1:
The patent applies local quality by achieving selective modulation of specific immune cell subsets (CD4+CD25+ regulatory T cells) and specific pathways (NF-κB) without affecting other systems. This selective approach allows disease-specific treatment effects while minimizing systemic side effects, as the compound locally modulates the relevant immune pathways without broad immunosuppression
3Adaptability or versatility
If broad-spectrum anti-inflammatory agents are used, then multiple disease conditions are treated, but lack of targeted specificity increases toxicity
Solution Approach 1:
The patent achieves universality through a single compound that can treat multiple disease conditions (autoimmune disorders, metabolic disorders, inflammation) by selectively modulating NF-κB and regulatory T cells. This multi-functional approach allows one agent to address diverse pathologies through a common mechanism, reducing the need for multiple specialized drugs and their associated toxicities
Data Source
AI summary
The invention relates to methods to identify compounds that can treat autoimmune conditions and treat specified clinical disorders such as multiple sclerosis, ulcerative colitis or arthritis. Compounds include 17α-ethynylandrost-5-ene-3β,11β,7α,17β-tetrol, 4α-acetoxy-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 17α-ethynylandrost-5-ene-3β,4β,7α,17β-tetrol, 17α-ethynylandrost-5-ene-3α,4β,7α,17β-tetrol and 17α-ethynylandrost-5-ene-3α,4β,17β-triol-7-one.